The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...

Cells contain a blueprint in the form of DNA that dictates what they can make. This blueprint is converted into a message ...

In a 2025 qualitative analysis of payer insights conducted by McKesson and Lumanity, 20 payers representing nearly 280 million covered lives reported that although they broadly view CGTs as safe (90%) ...

With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...

Mr Andrews contacted the medical team at Mass General Hospital ( MGH), the hospital in Massachusetts that had carried out the ...

The news for the chocolate industry is a welcome development, as businesses and scientists grapple with crop shortages.

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $72.31, marking a -2.24% move from the previous day.

We are now in the second great wave of the genetic revolution, not defined by reading the human code of life, but by ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...